Inside the secondary analysis, the much less conservative but clinically meaningful criterion of steady response (described like a fifty% or more reduction in MADRS from baseline for 2 months) was used. Of the patients who achieved stable reaction, 25.eight% during the esketamine group and 57.six% inside the placebo group relapsed, https://ermaa233xma0.wiki-jp.com/user